Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Public ClinicalTrials.gov record NCT02823574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714)
Study identification
- NCT ID
- NCT02823574
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 425 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2016
- Primary completion
- Jan 22, 2019
- Completion
- Apr 20, 2022
- Last update posted
- May 2, 2023
2016 – 2022
United States locations
- U.S. sites
- 28
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85724-5024 | — |
| Local Institution - 0034 | Duarte | California | 91010 | — |
| Los Angeles Cancer Network | Los Angeles | California | 90017 | — |
| Ucla Department Of Medicine | Los Angeles | California | 90095 | — |
| Local Institution - 0098 | Redondo Beach | California | 90277 | — |
| Local Institution - 0004 | Sacramento | California | 95816 | — |
| Local Institution - 0072 | San Francisco | California | 94158 | — |
| Local Institution - 0097 | San Luis Obispo | California | 93401 | — |
| Central Coast Med Oncology | Santa Maria | California | 93454 | — |
| Local Institution - 0101 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0007 | Tampa | Florida | 33612 | — |
| Local Institution - 0010 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0015 | Decatur | Georgia | 30033 | — |
| Local Institution - 0087 | Chicago | Illinois | 60637 | — |
| Ft. Wayne Med Onco-Hema Inc | Fort Wayne | Indiana | 46845 | — |
| Local Institution - 0005 | Louisville | Kentucky | 40202 | — |
| Oncology Associated Of Western Kentucky | Paducah | Kentucky | 42003 | — |
| Local Institution - 0001 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0071 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0042 | Rochester | Minnesota | 55905 | — |
| Mission Hospital, Inc | Asheville | North Carolina | 28801 | — |
| Local Institution - 0103 | Cincinnati | Ohio | 45219 | — |
| Local Institution - 0070 | Cleveland | Ohio | 44106 | — |
| Local Institution - 0008 | Portland | Oregon | 97239 | — |
| Local Institution - 0006 | Pittsburgh | Pennsylvania | 15232 | — |
| Donald Guthrie Foundation | Sayre | Pennsylvania | 18840 | — |
| Local Institution - 0102 | Dallas | Texas | 75390 | — |
| Local Institution - 0038 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02823574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02823574 live on ClinicalTrials.gov.